Daily Anesthesiology Research Analysis
Analyzed 132 papers and selected 3 impactful papers.
Summary
Across anesthesiology and perioperative medicine, a multicenter randomized trial found no long-term outcome differences between initial intraosseous and intravenous access for out-of-hospital cardiac arrest. A double-blind randomized trial in morbidly obese patients showed sugammadex accelerates diaphragmatic recovery and reduces postoperative pulmonary complications versus neostigmine. A meta-analysis of RCTs indicated liposomal bupivacaine offers statistically small, likely clinically trivial analgesic advantages after thoracoscopic lung surgery.
Research Themes
- Resuscitation strategy and vascular access in out-of-hospital cardiac arrest
- Neuromuscular reversal agents and respiratory protection in high-risk patients
- Value-based regional anesthesia pharmacology after thoracic surgery
Selected Articles
1. Effect of Vascular Access Strategy on Long-Term Outcomes in Patients with Out-of-hospital Cardiac Arrest A Randomised Clinical Trial.
In this randomized trial of 1,479 OHCA patients, initial intraosseous versus intravenous access produced similar 1-year survival (11% vs 9%) and favorable neurological outcomes (10% vs 8%). Quality-of-life among survivors was comparable, indicating no long-term outcome advantage for either access strategy.
Impact: Provides high-quality evidence that access strategy does not alter long-term outcomes, guiding EMS protocols and training priorities.
Clinical Implications: EMS systems can prioritize the most feasible, fastest, and safest access (IO or IV) based on context and operator skill without expecting long-term survival differences. Resource allocation and training can focus on minimizing delays and ensuring drug delivery rather than favoring one route.
Key Findings
- At 1 year, survival was 11% (IO) vs 9% (IV); risk ratio 1.24 (95% CI 0.91–1.67).
- Favorable neurological outcome was 10% (IO) vs 8% (IV); risk ratio 1.28 (95% CI 0.93–1.77).
- Among survivors, EQ-5D-5L numeric scores were similar (83 vs 76).
- No long-term outcome advantage of initial IO over IV (or vice versa) was observed.
Methodological Strengths
- Multicenter randomized design with prespecified long-term outcomes (6 months and 1 year).
- Large sample size with minimal loss to follow-up.
Limitations
- Blinding of access route was not feasible in the prehospital setting.
- Potential variability in prehospital care and protocol adherence across sites.
Future Directions: Investigate workflow, first-pass success, and time-to-drug delivery as mediators of outcome; evaluate combined strategies and device innovations to reduce delays.
OBJECTIVE: The Intravenous versus Intraosseous Vascular Access for Out-of-Hospital Cardiac Arrest (IVIO) trial was a randomised clinical trial that investigated initial vascular access strategy for out-of-hospital cardiac arrest. The current manuscript presents outcomes at 6 months and 1 year. METHODS: Adults with non-traumatic out-of-hospital cardiac arrest, in whom vascular access was indicated, were randomised to initial intraosseous or intravenous access. The allocated method was attempted up to two times. Prespecified 6-months and 1-year outcomes included survival, survival with a favourable neurological outcome, defined as a modified Rankin Scale score of 0 to 3, and health-related quality-of-life assessed using the EuroQoL 5-Dimension 5-Level questionnaire on domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. RESULTS: Of the 1,479 patients included in the main manuscript primary analyses, three were lost to follow-up for 1-year survival. At 1 year, 82 patients (11%) in the intraosseous group and 68 patients (9%) in the intravenous group were alive (risk ratio 1.24; 95% confidence interval 0.91-1.67). Survival with a favourable neurological outcome was observed in 76 patients (10%) and 61 patients (8%), respectively (risk ratio 1.28; 95% confidence interval 0.93-1.77). Among survivors, the mean EQ-5D-5L numeric score was 83 in the intraosseous group and 76 in the intravenous group (mean difference 7; 95% confidence interval 1-13). CONCLUSION: Long-term outcomes were similar between patients who received initial intraosseous versus intravenous vascular access during adult out-of-hospital cardiac arrest. These findings do not support a difference in patient outcomes between the two vascular access strategies. Trial registration EU Clinical Trials number 2022-500744-38-00; ClinicalTrials.gov number NCT05205031.
2. Impact of Sugammadex versus Neostigmine on Diaphragmatic Function and Respiratory Recovery in Morbidly Obese Patients with Moderate Neuromuscular Block: A Randomised Double-Blind Controlled Trial.
In morbidly obese patients with moderate neuromuscular block, sugammadex (2 mg/kg) yielded faster recovery of diaphragmatic excursion and thickening and better respiratory outcomes than neostigmine/atropine. The sugammadex group had a lower incidence of postoperative pulmonary complications.
Impact: Demonstrates physiologic and clinical advantages of sugammadex in a high-risk population, linking diaphragmatic function with fewer pulmonary complications.
Clinical Implications: For morbidly obese patients, consider sugammadex over neostigmine to hasten respiratory recovery and potentially reduce postoperative pulmonary complications; bedside diaphragmatic ultrasound can serve as a meaningful recovery marker.
Key Findings
- Sugammadex accelerated recovery of diaphragmatic excursion and thickening at 10–30 minutes post-extubation.
- Respiratory outcomes improved with sugammadex versus neostigmine.
- Lower incidence of postoperative pulmonary complications was observed with sugammadex.
Methodological Strengths
- Randomized double-blind controlled design.
- Objective, operator-independent endpoints using diaphragmatic ultrasound metrics.
Limitations
- Operator variability and learning curve in diaphragmatic ultrasound may affect measurements.
- Follow-up for postoperative pulmonary complications not fully detailed in abstract.
Future Directions: Confirm findings in multicenter trials, quantify effect sizes on specific pulmonary complications, and evaluate cost-effectiveness and recovery room workflows.
PURPOSE: Compared with neostigmine, sugammadex promotes faster neuromuscular recovery, but its impact on diaphragmatic function and respiratory recovery in the morbidly obese cohort, and the mechanism underlying its reduction of postoperative pulmonary complications remain unclear. This study aims to compare the effects of sugammadex and neostigmine on diaphragmatic function and respiratory recovery in morbidly obese patients after surgery, and to investigate the role of diaphragmatic function in the reduction of sugammadex-associated postoperative pulmonary complications. PATIENTS AND METHODS: For neuromuscular blockade reversal, 104 morbidly obese patients with moderate neuromuscular block (train-of-four count = 2, ratio <0.9) were randomly assigned to receive either neostigmine (50 μg kg-1+atropine 20 μg kg-1, n=51) or sugammadex (2 mg kg-1, n=53). Measurements of diaphragmatic excursion (DE) and thickening fraction (TF) were taken during deep and quiet breathing at T0 (baseline), T1 (10 min), and T2 (30 min) after extubation. The primary outcome measure was the change in deep breathing diaphragmatic excursion (ΔDE RESULTS: At T2, the ΔDE CONCLUSION: In morbid obesity, sugammadex promotes faster diaphragmatic recovery and improves respiratory outcomes compared with neostigmine and is associated with a lower incidence of postoperative pulmonary complications.
3. Effect of Liposomal Bupivacaine in Peripheral Nerve Block Following Thoracoscopic Lung Surgery: A Systematic Review and Meta-Analysis.
Across 9 RCTs (n=930), liposomal bupivacaine modestly reduced pain scores at rest and movement through 72 hours and lowered opioid use at 24 and 72 hours versus conventional local anesthetics. However, effect sizes were small and likely not clinically meaningful; 48-hour opioid use and PONV were unchanged, and heterogeneity was substantial.
Impact: Synthesis of RCT evidence tempers enthusiasm for premium liposomal formulations in thoracic procedures, supporting value-based analgesic choices.
Clinical Implications: When planning peripheral nerve blocks for thoracoscopic lung surgery, conventional local anesthetics remain appropriate; routine liposomal bupivacaine use may not justify added cost given small benefits and high heterogeneity.
Key Findings
- Liposomal bupivacaine reduced resting VAS at 24 h (MD −0.65), 48 h (MD −0.45), and 72 h (MD −0.33).
- Movement VAS reductions at 24/48/72 h were statistically significant but small; heterogeneity was high (e.g., I2=96% at 48 h).
- Opioid consumption decreased at 24 h (MD −2.68 mg morphine eq.) and 72 h (MD −8.76 mg), but not at 48 h; PONV showed no difference.
Methodological Strengths
- Meta-analysis restricted to randomized controlled trials with predefined outcomes.
- Consistent evaluation across multiple postoperative time points with random-effects modeling.
Limitations
- Substantial heterogeneity across trials; limited data on long-term analgesia and functional outcomes.
- Clinical significance of statistically small differences is questionable; cost-effectiveness not addressed.
Future Directions: Well-powered pragmatic RCTs with standardized ERAS pathways, cost-effectiveness analyses, and patient-centered outcomes (sleep, activity, return to function) are needed.
BACKGROUND: This systematic review and meta-analysis aims to compare liposomal bupivacaine (LB) with conventional local anesthetics (LAs) in peripheral nerve block following thoracoscopic lung surgery. METHODS: Randomized controlled trials (RCTs) evaluating LB and other LAs for postoperative analgesia were retrieved from databases, including PubMed, Embase, Cochrane Library, and Web of Sciencefrom inception to December 2025. The primary outcome was resting Visual Analogue Scale (VAS) at 24 hours. RESULTS: We included 9 RCTs with 930 patients. The LB had a lower resting VAS at 24 hours (mean difference [MD] = -0.65, 95% confidence interval [CI]: -0.83 to -0.47). Similar results were shown in the resting VAS at 48 hours (MD = -0.45, 95% CI: -0.61 to -0.29), resting VAS at 72 hours (MD = -0.33, 95% CI: -0.56 to -0.10), movement VAS at 24 hours (MD = -0.60, 95% CI: -0.75 to -0.45), movement VAS at 48 hours (MD = -0.46, 95% CI: -0.71 to -0.21; I2 = 96%), and movement VAS at 72 hours (MD = -0.60, 95% CI: -0.98 to -0.23). Additionally, LB reduced morphine consumption within 24 hours (MD = -2.68, 95% CI: -3.84 to -1.52) and morphine consumption within 72 hours (MD = -8.76, 95% CI: -16.13 to -1.38). However, there were no significant differences between LB and other LAs in morphine consumption within 48 hours and postoperative nausea and vomiting (PONV). CONCLUSION: Although LB produced statistically significant reductions in resting and movement pain scores at 24, 48, and 72 hours, as well as lower morphine consumption at 24 and 72 hours, the magnitude of these differences is unlikely to be clinically meaningful. Furthermore, no significant differences were observed for 48-hour morphine consumption or PONV. LIMITATION: The results showed many heterogeneity. There was a lack of data on long-term analgesia and functional outcomes.